In patients carrying AML mutated for DNMT3A and FLT3 (2022 OHSU repository in cBioPortal), low expression of FHIT correlates with reduced overall survival, suggesting that these patients could potentially benefit from DCPS targeted therapy (Fig. 1G). This evidence concerns the gene FLT3 and acute myeloid leukemia.